Go to Patients & Caregivers Site
Customer Contact Center:
1-888-PLMZYME (756-9963)

Indication Statement:

Daily administration of Pulmozyme (dornase alfa) in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than twelve months.

Important Safety Information

  • Pulmozyme should not be used in patients with known hypersensitivity to dornase alfa, or any ingredients of the product.
  • Pulmozyme should be used in conjunction with standard therapies for CF.
  • Most common reported adverse events associated with the use of Pulmozyme include: voice alteration, pharyngitis, laryngitis, rash, chest pain, and conjunctivitis.

Pulmozyme Access Solutions®

Prescribing Pulmozyme

Prescribing Pulmozyme

A standard part of CF care

Pulmozyme has been a standard part of CF care for over 17 years. In a multiple therapy approach for optimal disease management, Pulmozyme plays an essential role by:

  • Reducing the relative risk for exacerbations in patients with mild to moderate CF
  • Improving lung function (Ref. 1)

Because of the limited experience with the administration of Pulmozyme to patients younger than 5 years of age, its use should be considered only for those patients in whom there is a potential benefit for:

  • Pulmonary function
  • Risk of respiratory tract infection (Ref. 1)
Next:
Pulmozyme Treatment ›
References
  1. Pulmozyme Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2005. Pulmozyme PI:1.